Atara Biotherapeutics moving research division to Thousand Oaks

Atara Biotherapeutics will move its research and development division from Westlake Village to Thousand Oaks, the company said in a news release. The company plans to occupy 91,000 square feet at the yet-to-be-constructed Conejo Spectrum Business Park off of Lawrence Drive and Conejo Spectrum Street. The Sares-Regis Group bought 29 acres of land at the Read More →
FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →

Amgen funds STEM program for Girl Scouts

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen beats analyst estimates for fourth quarter revenue

Thousand Oaks-based biotech giant Amgen reported revenue of $6 billion in the fourth quarter of 2016, besting analyst estimates of $5.74 billion and increasing 8 percent from the fourth quarter of 2015. The world’s largest biotech drug maker posted total revenues of $23 billion on the year, up 6 percent from 2015. Revenue gains were Read More →
Agilent cancer treatment approved in Europe

Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
Amgen CEO meets with Trump, vows to add 1,600 jobs

Amgen CEO Robert Bradway met with President Donald Trump on Jan. 31 and vowed to add 1,600 jobs, Bloomberg News reported. Trump told biotech leaders at a White House meeting that drug prices needed to come down and he would find a way to streamline the regulatory process. He has discussed having the government negotiate Read More →